Merck Current Ratio 2010-2024 | MRK
Current and historical current ratio for Merck (MRK) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Merck current ratio for the three months ending March 31, 2024 was 1.25.
| Merck Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-03-31 |
$31.45B |
$25.10B |
1.25 |
| 2023-12-31 |
$32.17B |
$25.69B |
1.25 |
| 2023-09-30 |
$31.95B |
$23.09B |
1.38 |
| 2023-06-30 |
$29.98B |
$23.39B |
1.28 |
| 2023-03-31 |
$33.40B |
$23.13B |
1.44 |
| 2022-12-31 |
$35.72B |
$24.24B |
1.47 |
| 2022-09-30 |
$33.56B |
$23.00B |
1.46 |
| 2022-06-30 |
$32.12B |
$23.17B |
1.39 |
| 2022-03-31 |
$31.18B |
$22.32B |
1.40 |
| 2021-12-31 |
$30.27B |
$23.87B |
1.27 |
| 2021-09-30 |
$31.06B |
$23.73B |
1.31 |
| 2021-06-30 |
$28.67B |
$21.91B |
1.31 |
| 2021-03-31 |
$26.91B |
$26.36B |
1.02 |
| 2020-12-31 |
$27.76B |
$27.33B |
1.02 |
| 2020-09-30 |
$26.58B |
$20.41B |
1.30 |
| 2020-06-30 |
$29.34B |
$22.18B |
1.32 |
| 2020-03-31 |
$26.17B |
$23.48B |
1.12 |
| 2019-12-31 |
$27.48B |
$22.22B |
1.24 |
| 2019-09-30 |
$26.14B |
$20.68B |
1.26 |
| 2019-06-30 |
$24.30B |
$20.09B |
1.21 |
| 2019-03-31 |
$25.35B |
$18.54B |
1.37 |
| 2018-12-31 |
$25.88B |
$22.21B |
1.17 |
| 2018-09-30 |
$26.84B |
$18.59B |
1.44 |
| 2018-06-30 |
$24.06B |
$18.13B |
1.33 |
| 2018-03-31 |
$24.09B |
$16.96B |
1.42 |
| 2017-12-31 |
$24.77B |
$18.61B |
1.33 |
| 2017-09-30 |
$27.92B |
$19.47B |
1.43 |
| 2017-06-30 |
$28.17B |
$18.76B |
1.50 |
| 2017-03-31 |
$31.53B |
$19.82B |
1.59 |
| 2016-12-31 |
$30.61B |
$17.20B |
1.78 |
| 2016-09-30 |
$29.44B |
$15.56B |
1.89 |
| 2016-06-30 |
$27.93B |
$14.92B |
1.87 |
| 2016-03-31 |
$28.77B |
$17.57B |
1.64 |
| 2015-12-31 |
$29.75B |
$19.20B |
1.55 |
| 2015-09-30 |
$28.57B |
$17.58B |
1.63 |
| 2015-06-30 |
$28.32B |
$17.51B |
1.62 |
| 2015-03-31 |
$32.93B |
$20.44B |
1.61 |
| 2014-12-31 |
$32.61B |
$18.40B |
1.77 |
| 2014-09-30 |
$34.72B |
$25.93B |
1.34 |
| 2014-06-30 |
$33.59B |
$17.93B |
1.87 |
| 2014-03-31 |
$41.24B |
$22.47B |
1.84 |
| 2013-12-31 |
$35.69B |
$17.87B |
2.00 |
| 2013-09-30 |
$37.77B |
$18.22B |
2.07 |
| 2013-06-30 |
$37.00B |
$18.40B |
2.01 |
| 2013-03-31 |
$35.24B |
$18.80B |
1.87 |
| 2012-12-31 |
$34.86B |
$18.35B |
1.90 |
| 2012-09-30 |
$36.23B |
$15.58B |
2.33 |
| 2012-06-30 |
$35.64B |
$16.91B |
2.11 |
| 2012-03-31 |
$34.34B |
$16.58B |
2.07 |
| 2011-12-31 |
$33.18B |
$16.25B |
2.04 |
| 2011-09-30 |
$34.11B |
$16.59B |
2.06 |
| 2011-06-30 |
$32.37B |
$15.76B |
2.05 |
| 2011-03-31 |
$31.02B |
$15.66B |
1.98 |
| 2010-12-31 |
$29.06B |
$15.64B |
1.86 |
| 2010-09-30 |
$27.76B |
$17.32B |
1.60 |
| 2010-06-30 |
$26.25B |
$15.42B |
1.70 |
| 2010-03-31 |
$28.25B |
$16.46B |
1.72 |
| 2009-12-31 |
$28.43B |
$15.64B |
1.82 |
| 2009-09-30 |
$29.67B |
$8.03B |
3.70 |
| 2009-06-30 |
$29.23B |
$11.51B |
2.54 |
| 2009-03-31 |
$26.19B |
$13.42B |
1.95 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$270.018B |
$59.283B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
